View Point: Disease Modification and Cell Secretome Based Approaches in Parkinson’s Disease: Are We on the Right Track?

References

• Weiner WJ. There is no Parkinson disease. Arch Neurol. 2008;65:705–708.
   PubMed Web of Science ®Google Scholar
• Przuntek H, Müller T, Riederer P. Diagnostic staging of Parkinson’s disease: conceptual aspects. J Neural Transm. 2004;111:201–216. doi:10.1007/s00702-003-0102-y
   PubMed Web of Science ®Google Scholar
• Balestrino R, Tunesi S, Tesei S, Lopiano L, Zecchinelli AL, Goldwurm S. Penetrance of Glucocerebrosidase (GBA) mutations in Parkinson’s disease: a Kin Cohort Study. Mov Disord. 2020;35:2111–2114. doi:10.1002/mds.28200
   PubMed Web of Science ®Google Scholar
• Greuel A, Trezzi JP, Glaab E, et al. GBA variants in Parkinson’s disease: clinical, metabolomic, and multimodal neuroimaging phenotypes. Mov Disord. 2020;35:2201–2210. doi:10.1002/mds.28225
   PubMed Web of Science ®Google Scholar
• Mullin S, Stokholm MG, Hughes D, et al. Brain microglial activation increased in Glucocerebrosidase (GBA) mutation carriers without Parkinson’s disease. Mov Disord. 2021;36:774–779.
   PubMed Web of Science ®Google Scholar
• Straniero L, Asselta R, Bonvegna S, et al. The SPID-GBA study: sex distribution, penetrance, incidence, and dementia in GBA-PD. Neurol Genet. 2020;6:e523. doi:10.1212/NXG.0000000000000523
   PubMed Web of Science ®Google Scholar
• Thaler A, Shenhar-Tsarfaty S, Shaked Y, et al. Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease. Sci Rep. 2020;10:9329. doi:10.1038/s41598-020-66319-9
   PubMed Web of Science ®Google Scholar
• Ahmed H, Abushouk AI, Gabr M, Negida A, Abdel-Daim MM. Parkinson’s disease and pesticides: a meta-analysis of disease connection and genetic alterations. Biomed Pharmacother. 2017;90:638–649. doi:10.1016/j.biopha.2017.03.100
   PubMed Web of Science ®Google Scholar
• Liu X, Ma T, Qu B, Ji Y, Liu Z. Pesticide-induced gene mutations and Parkinson disease risk: a meta-analysis. Genet Test Mol Biomarkers. 2013;17:826–832. doi:10.1089/gtmb.2013.0313
   PubMed Web of Science ®Google Scholar
• de Rijk MC, Launer LJ, Berger K, et al. Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S21–S23.
   PubMed Web of Science ®Google Scholar
• Deuschl G, Beghi E, Fazekas F, et al. The burden of neurological diseases in Europe: an analysis for the Global Burden of Disease Study 2017. Lancet Public Health. 2020;5:e551–e567. doi:10.1016/S2468-2667(20)30190-0
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323:548–560. doi:10.1001/jama.2019.22360
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Hornykiewicz O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien Klin Wochenschr. 1961;73:787–788. [German].
   PubMedGoogle Scholar
• Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism–chronic treatment with L-dopa. N Engl J Med. 1969;280:337–345. doi:10.1056/NEJM196902132800701
   PubMed Web of Science ®Google Scholar
• Liedhegner EA, Steller KM, Mieyal JJ. Levodopa activates apoptosis signaling kinase 1 (ASK1) and promotes apoptosis in a neuronal model: implications for the treatment of Parkinson’s disease. Chem Res Toxicol. 2011;24:1644–1652. doi:10.1021/tx200082h
   PubMed Web of Science ®Google Scholar
• Müller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev Neurother. 2013;13:707–718. doi:10.1586/ern.13.50
   PubMed Web of Science ®Google Scholar
• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol. 2006;5:677–687. doi:10.1016/S1474-4422(06)70521-X
   PubMed Web of Science ®Google Scholar
• Ramot Y, Nyska A, Maronpot RR, et al. Ninety-day local tolerability and toxicity study of ND0612, a novel formulation of levodopa/ carbidopa, administered by subcutaneous continuous infusion in minipigs. Toxicol Pathol. 2017;45:764–773. doi:10.1177/0192623317729891
   PubMed Web of Science ®Google Scholar
• Gannon M, Che P, Chen Y, Jiao K, Roberson ED, Wang Q. Noradrenergic dysfunction in Alzheimer’s disease. Front Neurosci. 2015;9:220. doi:10.3389/fnins.2015.00220
   PubMed Web of Science ®Google Scholar
• Moll G, Gsell W, Wichart I, Jellinger K, Riederer P. Cholinergic and monoaminergic neuromediator systems in DAT. Neuropathological and neurochemical findings. In: Maurer K, Riederer P, Beckmann H, editors. Alzheimer’s Disease. Epidemiology, Neuropathology, Neurochemistry, and Clinics. Vienna: Springer; 1990:235–243.
   Google Scholar
• Kuhn W, Müller T, Ilias N, Dieter Ρ. The neuroimmune hypothesis in Parkinson’s disease. Rev Neurosci. 1997;8:29–34. doi:10.1515/REVNEURO.1997.8.1.29
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Deuschl G. Neuroinflammation - a common thread in neurological disorders. Nat Rev Neurol. 2019;15:429–430. doi:10.1038/s41582-019-0227-8
   PubMed Web of Science ®Google Scholar
• Hirsch EC, Standaert DG. Ten unsolved questions about neuroinflammation in Parkinson’s disease. Mov Disord. 2021;36:16–24. doi:10.1002/mds.28075
   PubMed Web of Science ®Google Scholar
• Lane CA, Hardy J, Schott JM. Alzheimer’s disease. Eur J Neurol. 2018;25:59–70. doi:10.1111/ene.13439
   PubMed Web of Science ®Google Scholar
• Toricelli M, Pereira AAR, Souza AG, et al. Mechanisms of neuroplasticity and brain degeneration: strategies for protection during the aging process. Neural Regen Res. 2021;16:58–67. doi:10.4103/1673-5374.286952
   Web of Science ®Google Scholar
• Eliash S, Shteter N, Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J Neural Transm. 2005;112:991–1003. doi:10.1007/s00702-004-0254-4
   PubMed Web of Science ®Google Scholar
• Freestone PS, Chung KK, Guatteo E, Mercuri NB, Nicholson LF, Lipski J. Acute action of rotenone on nigral dopaminergic neurons–involvement of reactive oxygen species and disruption of Ca2+ homeostasis. Eur J Neurosci. 2009;30:1849–1859. doi:10.1111/j.1460-9568.2009.06990.x
   PubMed Web of Science ®Google Scholar
• Horger BA, Nishimura MC, Armanini MP, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci. 1998;18:4929–4937. doi:10.1523/JNEUROSCI.18-13-04929.1998
   PubMed Web of Science ®Google Scholar
• Jamal F. Immunotherapies targeting alpha-synuclein in Parkinson disease. Fed Pract. 2020;37:375–379.
   Google Scholar
• Kitani K, Minami C, Maruyama W, Kanai S, Ivy GO, Carrillo MC. Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (-)deprenyl. In: Advances in Research on Neurodegeneration. Vienna: Springer; 2000:139–156.
   Google Scholar
• Maruyama W, Takahashi T, Youdim M, Naoi M. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm. 2002;109:467–481. doi:10.1007/s007020200038
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Yi H, Akao Y, Yamaoka Y, Shamoto-Nagai M. Neuroprotection by propargylamines in Parkinson’s disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. In: Neuropsychiatric Disorders An Integrative Approach. Vienna: Springer; 2007:121–131.
   Google Scholar
• Beal MF, Oakes D, Shoulson I, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71:543–552. doi:10.1001/jamaneurol.2014.131
   PubMed Web of Science ®Google Scholar
• Gross RE, Watts RL, Hauser RA, et al. Intrastriatal transplantation of microcarrier-bound human retinal pigment epithelial cells versus sham surgery in patients with advanced Parkinson’s disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2011;10:509–519. doi:10.1016/S1474-4422(11)70097-7
   PubMed Web of Science ®Google Scholar
• Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006;59:459–466. doi:10.1002/ana.20737
   PubMed Web of Science ®Google Scholar
• Müller T, Öhm G, Eilert K, et al. Benefit on motor and non-motor behavior in a specialized unit for Parkinson’s disease. J Neural Transm. 2017;124:715–720. doi:10.1007/s00702-017-1701-3
   PubMed Web of Science ®Google Scholar
• Kopyov OV, Jacques D, Lieberman A, Duma CM, Rogers RL. Clinical study of fetal mesencephalic intracerebral transplants for the treatment of Parkinson’s disease. Cell Transplant. 1996;5:327–337. doi:10.1177/096368979600500221
   Web of Science ®Google Scholar
• Wenning GK, Odin P, Morrish P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson’s disease. Ann Neurol. 1997;42:95–107. doi:10.1002/ana.410420115
   PubMed Web of Science ®Google Scholar
• Freed CR, Zhou W, Breeze RE. Dopamine cell transplantation for Parkinson’s disease: the importance of controlled clinical trials. Neurotherapeutics. 2011;8:549–561. doi:10.1007/s13311-011-0082-9
   Web of Science ®Google Scholar
• Politis M, Oertel WH, Wu K, et al. Graft-induced dyskinesias in Parkinson’s disease: high striatal serotonin/dopamine transporter ratio. Mov Disord. 2011;26:1997–2003. doi:10.1002/mds.23743
   PubMed Web of Science ®Google Scholar
• Politis M, Piccini P. In vivo imaging of the integration and function of nigral grafts in clinical trials. Prog Brain Res. 2012;200:199–220.
   PubMed Web of Science ®Google Scholar
• Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med. 2008;14:504–506. doi:10.1038/nm1747
   PubMed Web of Science ®Google Scholar
• Kordower JH, Goetz CG, Chu Y, et al. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017;81:46–57. doi:10.1002/ana.24820
   Web of Science ®Google Scholar
• Olanow CW, Savolainen M, Chu Y, Halliday GM, Kordower JH. Temporal evolution of microglia and alpha-synuclein accumulation following foetal grafting in Parkinson’s disease. Brain. 2019;142:1690–1700. doi:10.1093/brain/awz104
   Web of Science ®Google Scholar
• Kordower JH, Dodiya HB, Kordower AM, et al. Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis. 2011;43(3):552–557. doi:10.1016/j.nbd.2011.05.001
   PubMed Web of Science ®Google Scholar
• Sian-Hulsmann J, Monoranu C, Strobel S, Riederer P. Lewy bodies: a spectator or salient killer? CNS Neurol Disord Drug Targets. 2015;14:947–955. doi:10.2174/1871527314666150317225659
   PubMed Web of Science ®Google Scholar
• Tullis GE, Spears K, Kirk MD. Immunological barriers to stem cell therapy in the central nervous system. Stem Cells Int. 2014;2014:507905. doi:10.1155/2014/507905
   Web of Science ®Google Scholar
• Itakura G, Kawabata S, Ando M, et al. Fail-safe system against potential tumorigenicity after transplantation of iPSC derivatives. Stem Cell Rep. 2017;8:673–684. doi:10.1016/j.stemcr.2017.02.003
   PubMed Web of Science ®Google Scholar
• Simonson OE, Domogatskaya A, Volchkov P, Rodin S. The safety of human pluripotent stem cells in clinical treatment. Ann Med. 2015;47:370–380. doi:10.3109/07853890.2015.1051579
   PubMed Web of Science ®Google Scholar
• Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67:715–725. doi:10.1002/ana.21995
   PubMed Web of Science ®Google Scholar
• Oda W, Fujita Y, Baba K, Moshizuki H, Niwa H, Yamashita T. Inhibition of repulsive guidance molecule-a protects dopaminergic neurons in a mouse model of Parkinson’s disease. Cell Death Dis. 2021;12:1–15. doi:10.1038/s41419-021-03469-2
   Web of Science ®Google Scholar
• Carlsson A. Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl. 1972;51:11–42.
   PubMedGoogle Scholar
• Rabey JM, Yarden J, Dotan N, Mechlovich D, Riederer P, Youdim MBH. Creation of a gene expression classifier for predicting Parkinson’s disease rate of progression. J Neural Transm. 2020;127:755–762. doi:10.1007/s00702-020-02194-y
   Web of Science ®Google Scholar
• Braak H, Rub U, Gai WP, Del TK. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm. 2003;110:517–536. doi:10.1007/s00702-002-0808-2
   PubMed Web of Science ®Google Scholar
• Halliday G, McCann H, Shepherd C. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson’s disease? Expert Rev Neurother. 2012;12:673–686. doi:10.1586/ern.12.47
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Is Braak staging valid for all types of Parkinson’s disease? J Neural Transm. 2019;126:423–431. doi:10.1007/s00702-018-1898-9
   PubMed Web of Science ®Google Scholar
• Nickels SL, Modamio J, Mendes-Pinheiro B, Monzel AS, Betsou F, Schwamborn JC. Reproducible generation of human midbrain organoids for in vitro modeling of Parkinson’s disease. Stem Cell Res. 2020;46:101870. doi:10.1016/j.scr.2020.101870
   Web of Science ®Google Scholar
• Weiner WJ. What do clinical trials tell us about treating patients. Parkinsonism Relat Disord. 2009;15:S34–S37. doi:10.1016/S1353-8020(09)70776-X
   PubMed Web of Science ®Google Scholar
• Mendes-Pinheiro B, Teixeira FG, Anjo SI, Manadas B, Behie LA, Salgado AJ. Secretome of undifferentiated neural progenitor cells induces histological and motor improvements in a rat model of Parkinson’s disease. Stem Cells Transl Med. 2018;7:829–838. doi:10.1002/sctm.18-0009
   Web of Science ®Google Scholar
• Pires AO, Teixeira FG, Mendes-Pinheiro B, Serra SC, Sousa N, Salgado AJ. Old and new challenges in Parkinson’s disease therapeutics. Prog Neurobiol. 2017;156:69–89.
   PubMed Web of Science ®Google Scholar
• Teixeira FG, Panchalingam KM, ssuncao-Silva R, et al. Modulation of the mesenchymal stem cell secretome using computer-controlled bioreactors: impact on neuronal cell proliferation, survival and differentiation. Sci Rep. 2016;6:27791. doi:10.1038/srep27791
   PubMed Web of Science ®Google Scholar
• Marques CR, Marote A, Mendes-Pinheiro B, Teixeira FG, Salgado AJ. Cell secretome based approaches in Parkinson’s disease regenerative medicine. Expert Opin Biol Ther. 2018;18:1235–1245. doi:10.1080/14712598.2018.1546840
   PubMed Web of Science ®Google Scholar
• Marote A, Teixeira FG, Mendes-Pinheiro B, Salgado AJ. MSCs-derived exosomes: cell-secreted nanovesicles with regenerative potential. Front Pharmacol. 2016;7:231. doi:10.3389/fphar.2016.00231
   PubMed Web of Science ®Google Scholar
• Mendes-Pinheiro B, Anjo SI, Manadas B, et al. Bone marrow mesenchymal stem cells’ secretome exerts neuroprotective effects in a Parkinson’s disease rat model. Front Bioeng Biotechnol. 2019;7:294. doi:10.3389/fbioe.2019.00294
   Web of Science ®Google Scholar
• Teixeira FG, Carvalho MM, Panchalingam KM, et al. Impact of the secretome of human mesenchymal stem cells on brain structure and animal behavior in a rat model of Parkinson’s disease. Stem Cells Transl Med. 2017;6:634–646. doi:10.5966/sctm.2016-0071
   PubMed Web of Science ®Google Scholar
• Assuncao-Silva RC, Mendes-Pinheiro B, Patricio P, et al. Exploiting the impact of the secretome of MSCs isolated from different tissue sources on neuronal differentiation and axonal growth. Biochimie. 2018;155:83–91. doi:10.1016/j.biochi.2018.07.026
   Web of Science ®Google Scholar
• Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R. Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci. 2017;18:1852. doi:10.3390/ijms18091852
   Web of Science ®Google Scholar
• Vizoso FJ, Eiro N, Costa L, et al. Mesenchymal stem cells in homeostasis and systemic diseases: hypothesis, evidences, and therapeutic opportunities. Int J Mol Sci. 2019;20:3738. doi:10.3390/ijms20153738
   PubMed Web of Science ®Google Scholar
• Pires AO, Mendes-Pinheiro B, Teixeira FG, et al. Unveiling the differences of secretome of human bone marrow mesenchymal stem cells, adipose tissue-derived stem cells, and human umbilical cord perivascular cells: a proteomic analysis. Stem Cells Dev. 2016;25:1073–1083. doi:10.1089/scd.2016.0048
   PubMed Web of Science ®Google Scholar
• Ji C, Xue GF, Lijun C, et al. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson’s disease by increasing expression of BNDF. Brain Res. 2016;1634:1–11. doi:10.1016/j.brainres.2015.09.035
   PubMed Web of Science ®Google Scholar
• Li Q, Wang Z, Xing H, Wang Y, Guo Y. Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson’s disease. Mol Ther Nucleic Acids. 2021;23:1334–1344. doi:10.1016/j.omtn.2021.01.022
   PubMedGoogle Scholar
• Pinnell JR, Cui M, Tieu K. Exosomes in Parkinson disease. J Neurochem. 2021;157:413–428.
   Web of Science ®Google Scholar
• Sun T, Ding ZX, Luo X, Liu QS, Cheng Y. Blood exosomes have neuroprotective effects in a mouse model of Parkinson’s disease. Oxid Med Cell Longev. 2020;2020:3807476. doi:10.1155/2020/3807476
   Web of Science ®Google Scholar
• Yang J, Luo S, Zhang J, et al. Exosome-mediated delivery of antisense oligonucleotides targeting alpha-synuclein ameliorates the pathology in a mouse model of Parkinson’s disease. Neurobiol Dis. 2021;148:105218. doi:10.1016/j.nbd.2020.105218
   Web of Science ®Google Scholar
• Kumar P, Jha NK, Jha SK, Ramani K, Ambasta RK. Tau phosphorylation, molecular chaperones, and ubiquitin E3 ligase: clinical relevance in Alzheimer’s disease. J Alzheimers Dis. 2015;43:341–361. doi:10.3233/JAD-140933
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Yi H, Inaba K, Akao Y, Shamoto-Nagai M. Mitochondria in neurodegenerative disorders: regulation of the redox state and death signaling leading to neuronal death and survival. J Neural Transm. 2009;116:1371–1381. doi:10.1007/s00702-009-0309-7
   PubMed Web of Science ®Google Scholar
• Chaplot K, Jarvela TS, Lindberg I. Secreted chaperones in neurodegeneration. Front Aging Neurosci. 2020;12:268. doi:10.3389/fnagi.2020.00268
   PubMed Web of Science ®Google Scholar
• Gracia P, Camino JD, Volpicelli-Daley L, Cremades N. Multiplicity of alpha-synuclein aggregated species and their possible roles in disease. Int J Mol Sci. 2020;21:8043. doi:10.3390/ijms21218043
   Web of Science ®Google Scholar
• Boonman Z, Isacson O. Apoptosis in neuronal development and transplantation: role of caspases and trophic factors. Exp Neurol. 1999;156:1–15. doi:10.1006/exnr.1999.7056
   Web of Science ®Google Scholar
• Mothe AJ, Coelho M, Huang L, et al. Delayed administration of the human anti-RGMa monoclonal antibody elezanumab promotes functional recovery including spontaneous voiding after spinal cord injury in rats. Neurobiol Dis. 2020;143:104995. doi:10.1016/j.nbd.2020.104995
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54:93–101. doi:10.1002/ana.10609
   PubMed Web of Science ®Google Scholar
• Isaksen TJ, Yamashita T. Repulsive guidance molecule A regulates adult neurogenesis via the neogenin receptor. Neurosci Insights. 2020;15:2633105520948481. doi:10.1177/2633105520948481
   Google Scholar
• Korecka JA, Moloney EB, Eggers R, et al. Repulsive Guidance Molecule a (RGMa) induces neuropathological and behavioral changes that closely resemble Parkinson’s disease. J Neurosci. 2017;37:9361–9379. doi:10.1523/JNEUROSCI.0084-17.2017
   PubMed Web of Science ®Google Scholar
• Muller T, Barghorn S, Lutge S, et al. Decreased levels of repulsive guidance molecule A in association with beneficial effects of repeated intrathecal triamcinolone acetonide application in progressive multiple sclerosis patients. J Neural Transm. 2015;122:841–848. doi:10.1007/s00702-014-1308-x
   PubMed Web of Science ®Google Scholar
• Robinson RA, Griffiths SC, van de Haar LL, et al. Simultaneous binding of guidance cues NET1 and RGM blocks extracellular NEO1 signaling. Cell. 2021;184:2103–2120.e31. doi:10.1016/j.cell.2021.02.045
   Web of Science ®Google Scholar
• Satoh J, Tabunoki H, Ishida T, Saito Y, Arima K. Accumulation of a repulsive axonal guidance molecule RGMa in amyloid plaques: a possible hallmark of regenerative failure in Alzheimer’s disease brains. Neuropathol Appl Neurobiol. 2013;39:109–120. doi:10.1111/j.1365-2990.2012.01281.x
   Web of Science ®Google Scholar
• Muller T, Trommer I, Muhlack S, Mueller BK. Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson’s disease. J Neural Transm. 2016;123:401–406. doi:10.1007/s00702-016-1519-4
   PubMed Web of Science ®Google Scholar
• Babitt JL, Zhang Y, Samad TA, et al. Repulsive guidance molecule (RGMa), a DRAGON homologue, is a bone morphogenetic protein co-receptor. J Biol Chem. 2005;280:29820–29827. doi:10.1074/jbc.M503511200
   PubMed Web of Science ®Google Scholar
• Key B, Lah GJ. Repulsive guidance molecule A (RGMa): a molecule for all seasons. Cell Adh Migr. 2012;6:85–90. doi:10.4161/cam.20167
   PubMed Web of Science ®Google Scholar
• Malinauskas T, Peer TV, Bishop B, Mueller TD, Siebold C. Repulsive guidance molecules lock growth differentiation factor 5 in an inhibitory complex. Proc Natl Acad Sci USA. 2020;117:15620–15631. doi:10.1073/pnas.2000561117
   Web of Science ®Google Scholar
• Kubo T, Tokita S, Yamashita T. Repulsive guidance molecule-a and demyelination: implications for multiple sclerosis. J Neuroimmune Pharmacol. 2012;7:524–528. doi:10.1007/s11481-011-9334-z
   PubMed Web of Science ®Google Scholar
• Mothe AJ, Tassew NG, Shabanzadeh AP, et al. RGMa inhibition with human monoclonal antibodies promotes regeneration, plasticity and repair, and attenuates neuropathic pain after spinal cord injury. Sci Rep. 2017;7:10529. doi:10.1038/s41598-017-10987-7
   PubMed Web of Science ®Google Scholar
• Charish J, Shabanzadeh AP, Chen D, et al. Neogenin neutralization prevents photoreceptor loss in inherited retinal degeneration. J Clin Invest. 2020;130:2054–2068. doi:10.1172/JCI125898
   Web of Science ®Google Scholar
• Shabanzadeh AP, Tassew NG, Szydlowska K, et al. Uncoupling Neogenin association with lipid rafts promotes neuronal survival and functional recovery after stroke. Cell Death Dis. 2015;6:e1744. doi:10.1038/cddis.2015.109
   Web of Science ®Google Scholar
• Castonguay AM, Gravel C, Lévesque M. Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions. J Parkinsons Dis. 2021;11(1):71–92. doi:10.3233/JPD-202221
   Google Scholar
• Emamzadeh FN, Surguchov A. Parkinson’s disease: biomarkers, treatment, and risk factors. Front Neurosci. 2018;12:612. doi:10.3389/fnins.2018.00612
   PubMed Web of Science ®Google Scholar
• Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting alpha-synuclein as a therapy for Parkinson’s disease. Front Mol Neurosci. 2019;12:299. doi:10.3389/fnmol.2019.00299
   PubMed Web of Science ®Google Scholar
• Teng JS, Ooi YY, Chye SM, Ling APK, Koh RY. Immunotherapies for Parkinson’s disease: progression of clinical development. CNS Neurol Disord Drug Targets. 2021;20. Epub ahead of print. doi:10.2174/1871527320666210526160926
   Web of Science ®Google Scholar
• Brys M, Fanning L, Hung S, et al. Randomized phase I clinical trial of anti-alpha-synuclein antibody BIIB054. Mov Disord. 2019;34:1154–1163. doi:10.1002/mds.27738
   PubMed Web of Science ®Google Scholar
• Meissner WG, Traon AP, Foubert-Samier A, et al. A phase 1 randomized trial of specific active alpha-synuclein immunotherapies PD01A and PD03A in multiple system atrophy. Mov Disord. 2020;35:1957–1965. doi:10.1002/mds.28218
   Web of Science ®Google Scholar
• Volc D, Poewe W, Kutzelnigg A, et al. Safety and immunogenicity of the alpha-synuclein active immunotherapeutic PD01A in patients with Parkinson’s disease: a randomised, single-blinded, phase 1 trial. Lancet Neurol. 2020;19:591–600. doi:10.1016/S1474-4422(20)30136-8
   PubMed Web of Science ®Google Scholar
• Song M, Tian F, Xia H, Xie Y. Repulsive guidance molecule a suppresses seizures and mossy fiber sprouting via the FAKp120RasGAPRas signaling pathway. Mol Med Rep. 2019;19:3255–3262.
   Web of Science ®Google Scholar
• Tanabe S, Yamashita T. Repulsive guidance molecule-a is involved in Th17-cell-induced neurodegeneration in autoimmune encephalomyelitis. Cell Rep. 2014;9:1459–1470. doi:10.1016/j.celrep.2014.10.038
   PubMed Web of Science ®Google Scholar
• Chen J, Shifman MI. Inhibition of neogenin promotes neuronal survival and improved behavior recovery after spinal cord injury. Neuroscience. 2019;408:430–447. doi:10.1016/j.neuroscience.2019.03.055
   PubMed Web of Science ®Google Scholar
• Nakagawa H, Ninomiya T, Yamashita T, Takada M. Treatment with the neutralizing antibody against repulsive guidance molecule-a promotes recovery from impaired manual dexterity in a primate model of spinal cord injury. Cereb Cortex. 2019;29:561–572. doi:10.1093/cercor/bhx338
   PubMed Web of Science ®Google Scholar
• Yang W, Sun P. Promoting functions of microRNA-29a/199B in neurological recovery in rats with spinal cord injury through inhibition of the RGMA/STAT3 axis. J Orthop Surg Res. 2020;15:427. doi:10.1186/s13018-020-01956-4
   PubMed Web of Science ®Google Scholar
• Isaksen TJ, Fujita Y, Yamashita T. Repulsive guidance molecule A suppresses adult neurogenesis. Stem Cell Rep. 2020;14:677–691. doi:10.1016/j.stemcr.2020.03.003
   Web of Science ®Google Scholar
• Tian C, Shi H, Xiong S, Hu F, Xiong WC, Liu J. The neogenin/DCC homolog UNC-40 promotes BMP signaling via the RGM protein DRAG-1 in C. elegans. Development. 2013;140:4070–4080. doi:10.1242/dev.099838
   Web of Science ®Google Scholar
• Guarnieri G, Sarchielli E, Vannelli GB, Morelli A. Cell-based therapy in Alzheimer’s disease: can human fetal cholinergic neurons “untangle the skein”? Neural Regen Res. 2018;13:2105–2107. doi:10.4103/1673-5374.241459
   Web of Science ®Google Scholar
• Liu Z, Cheung HH. Stem cell-based therapies for Parkinson disease. Int J Mol Sci. 2020;21:8060. doi:10.3390/ijms21218060
   Web of Science ®Google Scholar
• Schweyer K, Ruschoff-Steiner C, Arias-Carrion O, Oertel WH, Rosler TW, Hoglinger GU. Neuronal precursor cells with dopaminergic commitment in the rostral migratory stream of the mouse. Sci Rep. 2019;9:13359. doi:10.1038/s41598-019-49920-5
   Web of Science ®Google Scholar
• Desplats P, Spencer B, Crews L, et al. Alpha-synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of Notch1. J Biol Chem. 2012;287:31691–31702. doi:10.1074/jbc.M112.354522
   PubMed Web of Science ®Google Scholar
• Winner B, Regensburger M, Schreglmann S, et al. Role of alpha-synuclein in adult neurogenesis and neuronal maturation in the dentate gyrus. J Neurosci. 2012;32:16906–16916. doi:10.1523/JNEUROSCI.2723-12.2012
   PubMed Web of Science ®Google Scholar
• Winner B, Marchetto MC, Winkler J, Gage FH. Human-induced pluripotent stem cells pave the road for a better understanding of motor neuron disease. Hum Mol Genet. 2014;23:R27–R34. doi:10.1093/hmg/ddu205
   Web of Science ®Google Scholar